Literature DB >> 17504183

Nitrogen-containing heterocyclic quinones: a class of potential selective antitumor agents.

Laura Garuti1, Marinella Roberti, Daniela Pizzirani.   

Abstract

The development of prodrugs that are enzymatically activated into anticancer agents is a promising perspective in cancer therapy. Many nitrogen-containing quinoid heterocycles have been reported to show antitumor effect. The principal interest in these compounds lies on their potential to produce tumor-selective toxicity. Selectivity occurs by difference in oxygen tension between normal and tumor tissue and by levels of the required activating enzymes. In this review a summary of the most interesting heterocyclic quinones is given together with their biological property. SAR studies concerning the importance of some structural features will be described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504183     DOI: 10.2174/138955707780619626

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  13 in total

1.  Late-Stage C-H Alkylation of Heterocycles and 1,4-Quinones via Oxidative Homolysis of 1,4-Dihydropyridines.

Authors:  Álvaro Gutiérrez-Bonet; Camille Remeur; Jennifer K Matsui; Gary A Molander
Journal:  J Am Chem Soc       Date:  2017-08-23       Impact factor: 15.419

2.  Theoretical investigation of the radical scavenging activity of shikonin and acylshikonin derivatives.

Authors:  Ruifa Jin; Yin Bai
Journal:  J Mol Model       Date:  2011-07-15       Impact factor: 1.810

3.  2-(chromon-3-yl)imidazole derivatives as potential antimicrobial agents: synthesis, biological evaluation and molecular docking studies.

Authors:  Shweta Sharma; Vishal Sharma; Gurpreet Singh; Harpreet Kaur; Shubham Srivastava; Mohan Paul S Ishar
Journal:  J Chem Biol       Date:  2016-11-16

4.  Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.

Authors:  Yakini Brandy; Innocent Ononiwu; Dolapo Adedeji; Vonetta Williams; Claudia Mouamba; Yasmine Kanaan; Robert L Copeland; Dwayne A Wright; Ray J Butcher; Samuel R Denmeade; Oladapo Bakare
Journal:  Invest New Drugs       Date:  2011-01-18       Impact factor: 3.850

Review 5.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

6.  Protonation Sites, Tandem Mass Spectrometry and Computational Calculations of o-Carbonyl Carbazolequinone Derivatives.

Authors:  Maximiliano Martínez-Cifuentes; Graciela Clavijo-Allancan; Pamela Zuñiga-Hormazabal; Braulio Aranda; Andrés Barriga; Boris Weiss-López; Ramiro Araya-Maturana
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

7.  Flavoenzyme-mediated reduction reactions and antitumor activity of nitrogen-containing tetracyclic ortho-quinone compounds and their nitrated derivatives.

Authors:  Milda Peciukaityte-Alksne; Jonas Šarlauskas; Lina Miseviciene; Audrone Maroziene; Narimantas Cenas; Kastis Krikštopaitis; Zita Staniulyte; Žilvinas Anusevicius
Journal:  EXCLI J       Date:  2017-05-11       Impact factor: 4.068

8.  Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative.

Authors:  Keum-Joo Son; Ki Ryung Choi; Chung-Kyu Ryu; Seog Jae Lee; Ho Jeong Kim; Hyunah Lee
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

9.  Cytotoxic Compounds from Aloe megalacantha.

Authors:  Negera Abdissa; Sebastian Gohlke; Marcel Frese; Norbert Sewald
Journal:  Molecules       Date:  2017-07-07       Impact factor: 4.411

10.  Synthesis and characterization of novel unsymmetrical and symmetrical 3-halo- or 3-methoxy-substituted 2-dibenzoylamino-1,4-naphthoquinone derivatives.

Authors:  Yakini Brandy; Nailah Brandy; Emmanuel Akinboye; Malik Lewis; Claudia Mouamba; Seshat Mack; Ray J Butcher; Alan J Anderson; Oladapo Bakare
Journal:  Molecules       Date:  2013-02-04       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.